Core Viewpoint - Protagonist Therapeutics (PTGX) experienced a significant stock price increase following the FDA approval of its partner Johnson & Johnson's icotrokinra for treating moderate-to-severe plaque psoriasis, indicating positive market sentiment towards the company and its product pipeline [2]. Group 1: Stock Performance - PTGX shares rose by 4.7% to $101.68 in the last trading session, with trading volume higher than average, contributing to a total gain of 17% over the past four weeks [1][2]. - The consensus EPS estimate for PTGX has been revised 10.7% higher over the last 30 days, suggesting potential for future price appreciation [4]. Group 2: Financial Expectations - Protagonist Therapeutics is expected to report a quarterly loss of $0.65 per share, reflecting a year-over-year decline of 242.1%, with revenues projected at $5 million, down 82.3% from the previous year [3]. - Despite the anticipated losses, trends in earnings estimate revisions are correlated with near-term stock price movements, indicating that positive revisions could lead to stock price strength [3][4]. Group 3: Industry Context - Protagonist Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Certara, Inc. (CERT) is another player, having closed 1.8% lower at $6.38, with a return of -0.5% over the past month [5]. - Certara's consensus EPS estimate has decreased by 18.5% over the past month, indicating a challenging outlook compared to Protagonist Therapeutics [6].

Protagonist Therapeutics FY Conference Summary Company Overview - Protagonist Therapeutics focuses on innovation through novel peptides, with expertise in both injectable and oral peptides since 2008, a time when peptides were largely overlooked [8][9] - The company went public in 2016 with the assistance of Barclays [4] Key Assets and Developments - **Icotrokinra**: An oral IL-23 blocker, the first of its kind, with phase 3 data showing promise. Approval is sought for psoriasis, with additional studies in psoriatic arthritis, ulcerative colitis, and Crohn's disease [9][10][12] - **Rusfertide**: A weekly injectable mimetic of hepcidin, targeting polycythemia vera, with a partnership with Takeda established in January 2024. Priority review has been granted, potentially accelerating approval [14][15][16] - Both drugs are expected to be approved in Q3 2026, marking significant milestones for the company [15] Future Pipeline - Protagonist is developing an oral IL-17 program and has preclinical studies in IL-4, aiming to create a portfolio of oral peptides to differentiate from existing injectable options [19][22][27] - The company is also working on an oral triple GLP-GIP-GCG for obesity, with clinical studies expected to begin in the second half of the year [25][131] Clinical Strategy and Evaluation - The company emphasizes rigorous preclinical evaluation to ensure oral bioavailability and efficacy, taking longer than typical assessments to select the right candidates [36][38] - For icotrokinra, J&J is leading the launch strategy, leveraging extensive data from head-to-head studies against competitors [41][45] Competitive Landscape - Protagonist acknowledges competition in the hepcidin space but believes their approach of creating a mimetic offers a distinct advantage over others enhancing endogenous hepcidin production [62][66][70] - The company is confident in its market position due to its early development stage and unique drug mechanisms [78] Business Development and Partnerships - Protagonist plans to take assets to clinical proof of concept before seeking partnerships for larger indications, while considering retaining more backend economics through creative cost-sharing arrangements [102][123] - The company aims to avoid external fundraising, focusing on internal funding for studies [125] Obesity Market Insights - The obesity treatment landscape is seen as a significant opportunity, with Protagonist aiming to differentiate through oral peptides in a crowded market [128][131] - The company is developing both weekly subcutaneous and daily oral formulations, with a focus on creating a diverse portfolio to address various patient needs [133][137] Conclusion - Protagonist Therapeutics is positioned to leverage its innovative peptide technology and strategic partnerships to address unmet medical needs in various therapeutic areas, particularly in immunology and obesity, while maintaining a strong focus on clinical efficacy and market differentiation [131][140]

Protagonist Therapeutics Conference Call Summary Company Overview - **Company**: Protagonist Therapeutics (NasdaqGM:PTGX) - **Focus**: Peptide therapeutics, with a history of development since 2008, aiming to address unmet medical needs through innovative oral peptide solutions [5][6] Key Points and Arguments Product Pipeline and Development - **Late-Stage Assets**: Protagonist has two late-stage partnered assets expected to receive approval in 2026, with outstanding Phase 3 data [5][6] - **Partnerships**: Collaborations with big pharma, such as Takeda and Johnson & Johnson, provide financial flexibility and support for R&D [6][27] - **Rusfertide**: Targeting polycythemia vera, with a priority review received, aiming for approval in Q3 2026. The disease affects approximately 100,000 patients in the U.S. [14][15][18] - **Icotrokinra**: Partnered with J&J, targeting psoriasis with promising Phase 3 data and an NDA filed in July 2025, expected approval in Q3 2026 [29][30] Market Opportunities - **Rusfertide**: Addresses uncontrolled hematocrit levels in polycythemia vera, a significant unmet need in treatment options [17][18] - **Icotrokinra**: Positioned as the first oral IL-23 antagonist, with a large market opportunity as 75%-90% of injectable patients may switch to an oral option [34][35] - **Obesity Market**: Protagonist is developing oral triple agonists, which could treat billions of patients, differentiating from existing injectable options [77][78] Financial Aspects - **Royalty Structure**: For rusfertide, a 21% royalty on the first $1.5 billion in sales, increasing to 29% thereafter. This structure supports the decision to opt-out of full partnership with Takeda [20][21][23] - **Sales Milestones**: Expected sales milestones for icotrokinra and rusfertide combined are projected at $1.2 billion, with achievable targets [31][32] Future Developments - **PN-881**: Currently in Phase 1 studies, targeting IL-17 blockers, with data expected in Q3 2026 to determine further development [60][63] - **Anti-Obesity Candidates**: Development of both oral and subcutaneous triple agonists, with clinical proof of concept expected soon [78][83] - **Financial Stability**: The company has a strong balance sheet, allowing for continued investment in its pipeline without the need for shareholder dilution [92] Additional Important Insights - **Differentiation Strategy**: Protagonist aims to create unique solutions in crowded markets by focusing on oral formulations and addressing specific unmet needs [8][12] - **Safety and Efficacy**: Emphasis on the safety profile of new drugs, particularly for chronic conditions where long-term treatment is necessary [49][50] - **Market Dynamics**: The company is aware of the competitive landscape and is strategically positioning its products to capture market share from existing therapies [41][42] This summary encapsulates the key insights from the Protagonist Therapeutics conference call, highlighting the company's strategic direction, product pipeline, market opportunities, and financial outlook.

Core Insights - Johnson & Johnson announced long-term data from the QUASAR study showing that TREMFYA® (guselkumab) maintains clinical and endoscopic remission in ulcerative colitis patients over three years, with over 80% of patients in clinical remission and more than 50% in endoscopic remission at Week 140 [1][2]. Group 1: Clinical Efficacy - At Week 140, 80.8% of patients treated with TREMFYA® were in clinical remission, while 53.6% achieved endoscopic remission [1]. - 78.6% of patients experienced histo-endoscopic mucosal improvement (HEMI), indicating significant intestinal healing [1]. - Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, demonstrating sustained efficacy [1]. Group 2: Study Retention and Safety - Approximately 89% of eligible study participants completed treatment through Week 140, indicating high retention rates [1]. - No new safety concerns were reported during the study, reinforcing the long-term safety profile of TREMFYA® [1][2]. Group 3: Mechanism and Approval - TREMFYA® is the first and only approved dual-acting monoclonal antibody that blocks IL-23 and binds to CD64, targeting immune-mediated diseases [1][2]. - The drug has received FDA and European Commission approval for treating both moderately to severely active Crohn's disease and ulcerative colitis [1][2]. Group 4: Additional Research and Commitment - Johnson & Johnson presented 30 abstracts at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, highlighting ongoing research and commitment to inflammatory bowel disease treatments [1]. - Two other abstracts from Johnson & Johnson were recognized as Top 10 oral abstracts, showcasing the company's dedication to advancing treatment options [1].

Core Insights - Protagonist Therapeutics is poised for significant growth and value creation over the next 12 to 24 months, driven by two potential blockbuster drug approvals and launches, multiple clinical readouts, new discovery programs, and a strong cash position [3] Company Overview - Protagonist Therapeutics is participating in the 44th JPMorgan Healthcare Conference for the sixth consecutive year, indicating its established presence in the biotech sector [2] - The company is focused on completing a decade-long journey from concept to commercialization with two specific assets: icotrokinra, partnered with Johnson & Johnson, and rusfertide, partnered with Takeda [3] Development Pipeline - The company is highlighting its development candidates that target validated biological pathways, with differentiated assets aimed at addressing specific unmet medical needs across multiple indications [4]

Core Insights - Johnson & Johnson (J&J) has a strong R&D pipeline focused on immunology, oncology, and neuroscience, with significant advancements in 2025 [1][2][8] Pipeline and Product Approvals - J&J has achieved major clinical and regulatory milestones, including approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [2][11] - Nipocalimab is being evaluated for various immune-mediated conditions and is considered to have pipeline-in-a-product potential [3] - Regulatory applications for icotrokinra, an oral treatment for moderate-to-severe plaque psoriasis, have been filed in the US and EU [4] - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $2.14 billion in sales in the first nine months of 2025 [5][11] Strategic Acquisitions and Expansions - The acquisition of Intra-Cellular Therapies added Caplyta, an antidepressant, to J&J's neuroscience portfolio [6] - J&J aims to expand the indications of currently marketed products, with recent approvals for Tremfya, Rybrevant, and Caplyta [7] Long-term Growth Potential - J&J's pipeline execution and recent product approvals position the company for sustained growth beyond short-term pressures, with multiple late-stage assets and significant sales potential across its Innovative Medicine portfolio [8] Competitive Landscape - J&J faces competition in the oncology space from major players like Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with strong oncology portfolios and growth in sales [9][10][12][13][14] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 42.8% over the past year compared to a 17.5% increase for the industry [15] - The company's shares trade at a price/earnings ratio of 18.09, slightly above the industry average of 17.59 and its five-year mean of 15.65 [18] - The Zacks Consensus Estimate for 2025 earnings has increased from $10.86 to $10.87 per share, indicating positive earnings revisions [20]

Core Insights - Protagonist Therapeutics and Takeda announced new 52-week results from the Phase 3 VERIFY study, highlighting the efficacy and safety of rusfertide in treating polycythemia vera (PV) patients, with 61.9% of patients maintaining absence of phlebotomy eligibility from baseline to Week 52 [1][2] Efficacy and Safety - The 52-week data demonstrated sustained efficacy of rusfertide, significantly reducing the need for phlebotomy while maintaining hematocrit control [2] - 61.9% of patients treated with rusfertide maintained a durable clinical response, defined as absence of phlebotomy eligibility [4] - 84.1% of patients who had a clinical response in the Part 1a assessment maintained their response [4] - The median time to first phlebotomy was not reached in the rusfertide group, indicating effective treatment [4] Patient Outcomes - Patients treated with rusfertide reported improvements in quality of life, as measured by PROMIS Fatigue SF-8 and MFSAF TSS [4] - The mean hematocrit remained below 43% through Week 52 for patients treated with rusfertide [4] - Serious adverse events occurred in 8.1% of rusfertide-treated patients, indicating a generally well-tolerated safety profile [5] Long-term Study Insights - The THRIVE study showed a greater than 13-fold reduction in the estimated annual therapeutic phlebotomy rate compared to baseline, with a mean annualized phlebotomy rate dropping from 9.2 to 0.7 phlebotomies/year [6] - The THRIVE study is designed to assess the long-term durability of response and safety profile of rusfertide over an additional two-year treatment period [10] Regulatory and Development Status - Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA, indicating its potential as a significant treatment option for PV [7] - The Phase 3 VERIFY study is ongoing, evaluating rusfertide in 293 patients over a 156-week period [8]

Core Insights - The company is preparing for the potential launch of icotrokinra, a targeted oral peptide for psoriasis treatment, which is seen as a transformative next-generation therapy [1][2] - Icotrokinra is the only asset that offers a combination of complete skin clearance, favorable safety, and the convenience of a once-daily pill [1] - The development program for icotrokinra has been robust, supporting its position as a first-line systemic therapy for psoriasis based on large Phase III study data [2]

Core Insights - Icotrokinra, a first-in-class targeted oral peptide developed by Johnson & Johnson, has shown promising results in the Phase 2b ANTHEM-UC study for treating moderately to severely active ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement at Week 28 compared to placebo [1][2][3] Clinical Results - At Week 28, all doses of icotrokinra (100 mg, 200 mg, and 400 mg) demonstrated higher rates of clinical response, clinical remission, endoscopic improvement, and histologic-endoscopic mucosal improvement (HEMI) compared to placebo [1][2] - The clinical response rates for the 400 mg dose were 66.7% at Week 28, up from 63.5% at Week 12, while clinical remission improved from 30.2% to 31.7% [2] - Endoscopic improvement increased from 36.5% at Week 12 to 38.1% at Week 28, with HEMI rates rising from 28.6% to 33.1% [2] Safety Profile - Similar proportions of participants reported adverse events and serious adverse events across all icotrokinra dose groups and the placebo group, indicating a favorable safety profile [2][3] Future Development - Johnson & Johnson has initiated Phase 3 clinical development for icotrokinra in both adults and adolescents with moderately to severely active ulcerative colitis and Crohn's disease [3] - The company is also studying icotrokinra in pivotal Phase 3 programs for moderate-to-severe plaque psoriasis and active psoriatic arthritis [3][9] Mechanism of Action - Icotrokinra is designed to precisely block the IL-23 receptor, which plays a critical role in the inflammatory response associated with ulcerative colitis and other IL-23-mediated diseases [8][9] Regulatory Status - A New Drug Application (NDA) for icotrokinra was submitted to the U.S. Food and Drug Administration (FDA) in July 2025, seeking approval for treating adults and pediatric patients aged 12 years and older with moderate to severe plaque psoriasis [3]

Core Insights - Johnson & Johnson announced long-term data from the Phase 3 ICONIC-TOTAL study, showing that icotrokinra, a targeted oral peptide, effectively treats moderate-to-severe plaque psoriasis in adults and adolescents, achieving high rates of skin clearance [1][4][5]. Efficacy and Safety - In the ICONIC-TOTAL study, 72% of patients with scalp psoriasis and 85% with genital psoriasis achieved clear or almost clear skin at Week 52 [1][6]. - Overall, 67% of patients treated with icotrokinra achieved clear or almost clear skin by Week 24, maintaining this through Week 52 [1][4]. - In patients with hand/foot psoriasis, the rate of skin clearance increased from 42% at Week 16 to 62% at Week 52 [3]. Patient Impact - The study highlights the significant distress experienced by patients when psoriasis affects sensitive areas, indicating icotrokinra's potential as a meaningful treatment option for managing moderate-to-severe plaque psoriasis long-term [4][5]. - The treatment demonstrated comparable response rates between patients who received icotrokinra for the full 52 weeks and those who transitioned from placebo at Week 16 [4]. Clinical Development - The ICONIC clinical development program includes multiple studies evaluating icotrokinra's efficacy and safety across various conditions, including plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease [10][11][16]. - Icotrokinra is designed to precisely block the IL-23 receptor, which is crucial in the inflammatory response associated with these diseases [13][16]. Conclusion - The long-term data from the ICONIC-TOTAL study reinforces icotrokinra's potential to set a new standard of treatment for patients with high-impact psoriasis, combining effective skin clearance with a favorable safety profile [5][12].